2.34
+0.1157(+5.21%)
Currency In USD
| Previous Close | 2.22 |
| Open | 2.23 |
| Day High | 2.38 |
| Day Low | 2.22 |
| 52-Week High | 26.35 |
| 52-Week Low | 1.76 |
| Volume | 851,262 |
| Average Volume | 2.51M |
| Market Cap | 114.16M |
| PE | -1.08 |
| EPS | -2.16 |
| Moving Average 50 Days | 2.96 |
| Moving Average 200 Days | 6.94 |
| Change | 0.12 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $233.57 as of January 16, 2025 at a share price of $2.336. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $143.56 as of January 16, 2025 at a share price of $2.336.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and increased pace of enrollment with 44 active clinical
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
GlobeNewswire Inc.
Nov 26, 2024 1:00 PM GMT
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoim
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
GlobeNewswire Inc.
Nov 18, 2024 12:00 PM GMT
– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myosi